Global orthopedic sales totaled $62 billion in 2024, an increase of 5% compared to 2023. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
The Numbers
The company grew in the mid-single-digits during its fiscal 2025 on the strength of its differentiated enabling technology.
MSKai assists in the evaluation of previously acquired T2-weighted lumbar spine MRIs, performing measurement and export of results into customizable reports.
The company grew in the mid-single-digits during its fiscal 2025 on the strength of its differentiated enabling technology.
May 22, 2025
,
A look at the opportunities and issues facing three orthopedic market regions: Europe, China and Latin America.
May 21, 2025
,
A primer on normalizing procedure demand, the changing basis of competition, shifting M&A trends and current international opportunities.Â
May 20, 2025
,
The company grew in the low double digits in 1Q25 on the strength of new product introductions and robust international sales.
May 16, 2025
,
Through the first four months of the year, orthopedic funding is off to its slowest start in the last decade.
May 14, 2025
,
The company grew in the mid-teens and could see even greater demand with MACI Arthro’s use for trochlea defects.
May 14, 2025
,
Insight’s EmbedMed platform digitizes the surgical planning process and allows for rapid design and manufacture of patient-specific guides for orthopedic surgery.
May 14, 2025
,
The company’s orthopedic sales declined about 10% in the first quarter of 2025, but its commercial channel showed ample promise.
May 13, 2025
,
The company grew in the low single digits for the first quarter of 2025 and expects accelerating growth through the year.
May 13, 2025
,
Stay up to date on the orthopedic market’s 1Q performance in 2025 as we update this post with company sales data and industry developments.
May 12, 2025
,
The company faced market softness, supply issues and international order timing lumpiness as it declined in the low single digits.
May 12, 2025
,
The company’s orthopedic sales grew 6% in the first quarter of 2025 on the strength of DUROLANE and Exogen.
May 9, 2025
,
The company grew nearly 25% in the first quarter of 2025 as its physician user base reached record levels.
May 9, 2025
,
The company grew in the low single digits for 1Q25 due to one less selling day and distributor team transitions.
May 8, 2025
,
The company grew in the low single digits in the first quarter of 2025 and it retools its U.S. sales channel.
